Next 10 |
home / stock / vtyx / vtyx articles
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focus...
LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a cl...
NEW YORK, April 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ven...
NEW YORK, April 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vent...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the upcoming April 30, 2024 deadline to se...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ventyx Biosciences, Inc. ("Ventyx" or the &...
SAN DIEGO, April 17, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all those who...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ventyx Biosciences, Inc. (NASDAQ:...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focus...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...